Akari Therapeutics PLC (FRA:CLA)

€ 2.22 0.04 (1.83%) Market Cap: 26.95 Mil Enterprise Value: 23.99 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 17/100

Akari Therapeutics PLC To Host a Virtual Key Opinion Leader Event Transcript
Oct 19, 2023
Akari Therapeutics PLC at Emerging Growth Conference (Virtual) Transcript
Oct 04, 2023
Akari Therapeutics PLC To Host a Virtual Key Opinion Leader Event Transcript
May 22, 2023
Akari Therapeutics PLC at Sidoti & Company November Micro Cap Virtual Conference Transcript
Nov 09, 2022
Akari Therapeutics PLC Business Update Call Transcript
Aug 31, 2020

Akari Therapeutics PLC at Emerging Growth Conference (Virtual) Transcript

Oct 04, 2023 / 03:25PM GMT

Release Date Price: €3.58 (+6.55%)

Transcript

Ana Berry

Berry Media - Media

Welcome back, everyone. Next, we have Akari Therapeutics. Trades on the Nasdaq under the symbol AKTX. It's a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Please welcome its CEO, Rachelle Jacques. Nice to see you, Rachelle.

Rachelle Jacques

Akari Therapeutics, plc - President & CEO

Thanks, Ana. Welcome, everybody. As Ana said, I'm Rachelle Jacques, CEO of Akari Therapeutics. Really happy to be here with you today. Today, I will be making some forward-looking statements. Please be advised.

At Akari, we are a late-stage biotech company. We were formed in 2015, focused on our lead asset, nomacopan, which is a novel inhibitor of both complement C5 and leukotriene B4. So this is really to target proinflammatory pathways, and we believe will have application in a variety of autoimmune and inflammatory diseases. So broad potential here as we're looking at various applications. It's also important in biologics to have flexibility in the way that you treat patients with the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.